First Wave BioPharma (NASDAQ:FWBI) chairman, president and CEO James Sapirstein joined Proactive with details of the company's therapeutic development pipeline populated with multiple clinical stage programs built around its two proprietary technologies.
Sapirstein explained that adrulipase is a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients, while niclosamide is an oral small molecule with anti-viral and anti-inflammatory properties.
He said First Wave is developing these technologies for a host of gastrointestinal (GI) diseases where there are significant unmet clinical needs and limited therapeutic options.